{
  "success": true,
  "pagesUsed": [
    1,
    6,
    7,
    8,
    10,
    11,
    15,
    16,
    17,
    19,
    20,
    21,
    22,
    23
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "SYNOPSIS",
        "text": "SYNOPSIS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionTitle": "SYNOPSIS",
        "sectionType": {
          "id": "27f2ef73-144f-4c86-ab80-423c0f5e0bf9",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "TIME AND EVENTS SCHEDULE OVERVIEW",
        "text": "TIME AND EVENTS SCHEDULE OVERVIEW",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionTitle": "TIME AND EVENTS SCHEDULE OVERVIEW",
        "sectionType": {
          "id": "0088d34e-324e-4ab0-826f-8d87836e46a6",
          "code": "Study Procedures",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Procedures",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_3",
        "name": "TIME AND EVENTS SCHEDULE, DOSE ADMINISTRATION",
        "text": "TIME AND EVENTS SCHEDULE, DOSE ADMINISTRATION",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionTitle": "TIME AND EVENTS SCHEDULE, DOSE ADMINISTRATION",
        "sectionType": {
          "id": "23e63ba9-c334-42a0-94bb-cce9a5792982",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "ABBREVIATIONS",
        "text": "ABBREVIATIONS",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionTitle": "ABBREVIATIONS",
        "sectionType": {
          "id": "ce389627-f87d-43a9-b067-8e75c0d5c444",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_5",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "83fe4279-f8d0-4c6c-87aa-cbd1c49c7698",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2",
          "nci_5_3",
          "nci_5_4",
          "nci_5_5"
        ]
      },
      {
        "id": "nc_6",
        "name": "OBJECTIVES AND HYPOTHESIS",
        "text": "OBJECTIVES AND HYPOTHESIS",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "OBJECTIVES AND HYPOTHESIS",
        "sectionType": {
          "id": "2582697a-bd18-4843-a4cb-a22c0bd97cd6",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2"
        ]
      },
      {
        "id": "nc_7",
        "name": "STUDY DESIGN AND RATIONALE",
        "text": "STUDY DESIGN AND RATIONALE",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN AND RATIONALE",
        "sectionType": {
          "id": "75c29c59-635b-40aa-a67d-b90db3f3e5c5",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_7_1",
          "nci_7_2"
        ]
      },
      {
        "id": "nc_8",
        "name": "SUBJECT POPULATION",
        "text": "SUBJECT POPULATION",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "SUBJECT POPULATION",
        "sectionType": {
          "id": "614f770a-6785-4aa3-84a5-20788ee97032",
          "code": "Study Population",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Population",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_8_1",
          "nci_8_2",
          "nci_8_3"
        ]
      },
      {
        "id": "nc_9",
        "name": "TREATMENT ALLOCATION AND BLINDING",
        "text": "TREATMENT ALLOCATION AND BLINDING",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5",
        "sectionTitle": "TREATMENT ALLOCATION AND BLINDING",
        "sectionType": {
          "id": "4ce11707-7bc1-471c-ae9a-b3487a297b96",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_10",
        "name": "DOSAGE AND ADMINISTRATION",
        "text": "DOSAGE AND ADMINISTRATION",
        "order": 9,
        "instanceType": "NarrativeContent",
        "sectionNumber": "6",
        "sectionTitle": "DOSAGE AND ADMINISTRATION",
        "sectionType": {
          "id": "e3ad087e-3767-4126-8660-096b56dcfa25",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_10_1",
          "nci_10_2",
          "nci_10_3"
        ]
      },
      {
        "id": "nc_11",
        "name": "CONCOMITANT THERAPY",
        "text": "CONCOMITANT THERAPY",
        "order": 10,
        "instanceType": "NarrativeContent",
        "sectionNumber": "8",
        "sectionTitle": "CONCOMITANT THERAPY",
        "sectionType": {
          "id": "76cd13e9-e128-4a63-bb2b-ebeed2ecd6da",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_11_1",
          "nci_11_2",
          "nci_11_3"
        ]
      },
      {
        "id": "nc_12",
        "name": "STUDY EVALUATIONS",
        "text": "STUDY EVALUATIONS",
        "order": 11,
        "instanceType": "NarrativeContent",
        "sectionNumber": "9",
        "sectionTitle": "STUDY EVALUATIONS",
        "sectionType": {
          "id": "0e8c0a63-5123-4777-9f33-8530dc0a4c4f",
          "code": "Assessments",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Assessments",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_12_1",
          "nci_12_2",
          "nci_12_3",
          "nci_12_4"
        ]
      },
      {
        "id": "nc_13",
        "name": "STATISTICAL METHODS",
        "text": "STATISTICAL METHODS",
        "order": 12,
        "instanceType": "NarrativeContent",
        "sectionNumber": "11",
        "sectionTitle": "STATISTICAL METHODS",
        "sectionType": {
          "id": "3ba1e55c-bccc-4049-9865-a0f3e5b0d347",
          "code": "Statistics",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Statistics",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_13_1",
          "nci_13_2",
          "nci_13_3"
        ]
      },
      {
        "id": "nc_14",
        "name": "ADVERSE EVENT REPORTING",
        "text": "ADVERSE EVENT REPORTING",
        "order": 13,
        "instanceType": "NarrativeContent",
        "sectionNumber": "12",
        "sectionTitle": "ADVERSE EVENT REPORTING",
        "sectionType": {
          "id": "52fec018-c033-46c7-932a-6a9fee6bc005",
          "code": "Safety",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Safety",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_14_1",
          "nci_14_2"
        ]
      },
      {
        "id": "nc_15",
        "name": "STUDY ADMINISTRATION",
        "text": "STUDY ADMINISTRATION",
        "order": 14,
        "instanceType": "NarrativeContent",
        "sectionNumber": "17",
        "sectionTitle": "STUDY ADMINISTRATION",
        "sectionType": {
          "id": "a0f9db63-d2bb-4001-98b2-2a5718454ee2",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_15_1"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_5_1",
        "name": "Background",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Background"
      },
      {
        "id": "nci_5_2",
        "name": "Daratumumab",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Daratumumab"
      },
      {
        "id": "nci_5_3",
        "name": "Lenalidomide",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Lenalidomide"
      },
      {
        "id": "nci_5_4",
        "name": "Lenalidomide and Daratumumab",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.4",
        "sectionTitle": "Lenalidomide and Daratumumab"
      },
      {
        "id": "nci_5_5",
        "name": "Overall Rationale for the Study",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.5",
        "sectionTitle": "Overall Rationale for the Study"
      },
      {
        "id": "nci_6_1",
        "name": "Objectives",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Objectives"
      },
      {
        "id": "nci_6_2",
        "name": "Hypothesis",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Hypothesis"
      },
      {
        "id": "nci_7_1",
        "name": "Overview of Study Design",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Overview of Study Design"
      },
      {
        "id": "nci_7_2",
        "name": "Study Design Rationale",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Study Design Rationale"
      },
      {
        "id": "nci_8_1",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_8_2",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_8_3",
        "name": "Prohibitions and Restrictions",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3",
        "sectionTitle": "Prohibitions and Restrictions"
      },
      {
        "id": "nci_10_1",
        "name": "Daratumumab (Arm B Only)",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.1",
        "sectionTitle": "Daratumumab (Arm B Only)"
      },
      {
        "id": "nci_10_2",
        "name": "Lenalidomide (Arm A and Arm B)",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2",
        "sectionTitle": "Lenalidomide (Arm A and Arm B)"
      },
      {
        "id": "nci_10_3",
        "name": "Dexamethasone (Arm A and Arm B)",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.3",
        "sectionTitle": "Dexamethasone (Arm A and Arm B)"
      },
      {
        "id": "nci_11_1",
        "name": "Permitted Therapies",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.2",
        "sectionTitle": "Permitted Therapies"
      },
      {
        "id": "nci_11_2",
        "name": "Prohibited Therapies",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.3",
        "sectionTitle": "Prohibited Therapies"
      },
      {
        "id": "nci_11_3",
        "name": "Subsequent Therapies",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.4",
        "sectionTitle": "Subsequent Therapies"
      },
      {
        "id": "nci_12_1",
        "name": "Study Phases and Visit Conduct",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.1",
        "sectionTitle": "Study Phases and Visit Conduct"
      },
      {
        "id": "nci_12_2",
        "name": "Efficacy",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.2",
        "sectionTitle": "Efficacy"
      },
      {
        "id": "nci_12_3",
        "name": "Pharmacokinetics and Immunogenicity",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.3",
        "sectionTitle": "Pharmacokinetics and Immunogenicity"
      },
      {
        "id": "nci_12_4",
        "name": "Safety Evaluations",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.8",
        "sectionTitle": "Safety Evaluations"
      },
      {
        "id": "nci_13_1",
        "name": "Sample Size Determination",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "11.2",
        "sectionTitle": "Sample Size Determination"
      },
      {
        "id": "nci_13_2",
        "name": "Efficacy Analysis",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "11.3",
        "sectionTitle": "Efficacy Analysis"
      },
      {
        "id": "nci_13_3",
        "name": "Interim Analysis",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "11.10",
        "sectionTitle": "Interim Analysis"
      },
      {
        "id": "nci_14_1",
        "name": "All Adverse Events",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "12.3.1",
        "sectionTitle": "All Adverse Events"
      },
      {
        "id": "nci_14_2",
        "name": "Serious Adverse Events",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "12.3.2",
        "sectionTitle": "Serious Adverse Events"
      },
      {
        "id": "nci_15_1",
        "name": "Final OS Analysis/End of Study",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "17.9.1",
        "sectionTitle": "Final OS Analysis/End of Study"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "CSR",
        "expandedText": "Clinical Study Report",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "OS",
        "expandedText": "Overall Survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "PD",
        "expandedText": "Disease Progression",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "Dara-SC",
        "expandedText": "Daratumumab Subcutaneous",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "Dara-IV",
        "expandedText": "Daratumumab Intravenous",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "IRR",
        "expandedText": "Infusion-Related Reaction",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "rHuPH20",
        "expandedText": "Recombinant Human Hyaluronidase PH20",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "PFS",
        "expandedText": "Progression Free Survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "DRd",
        "expandedText": "Daratumumab plus Lenalidomide and Dexamethasone",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "IDMC",
        "expandedText": "Independent Data Monitoring Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "Rd",
        "expandedText": "Lenalidomide and Dexamethasone",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "IMWG",
        "expandedText": "International Myeloma Working Group",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "PK",
        "expandedText": "Pharmacokinetics",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "ECOG",
        "expandedText": "Eastern Cooperative Oncology Group",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "ePRO",
        "expandedText": "Electronic Patient-Reported Outcome",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "MRD",
        "expandedText": "Minimal Residual Disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "CR",
        "expandedText": "Complete Response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "sCR",
        "expandedText": "Stringent Complete Response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "C1D1",
        "expandedText": "Cycle 1 Day 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "PR",
        "expandedText": "Partial Response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "PC",
        "expandedText": "Plasma Cell",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "FLC",
        "expandedText": "Free Light Chain",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "ICMJE",
        "expandedText": "International Committee of Medical Journal Editors",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "G-CSF",
        "expandedText": "Granulocyte Colony-Stimulating Factor",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "MRU",
        "expandedText": "Medical Resource Utilization",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "eCRF",
        "expandedText": "Electronic Case Report Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "PBMC",
        "expandedText": "Peripheral Blood Mononuclear Cell",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "IHC",
        "expandedText": "Immunohistochemistry",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 15,
      "itemCount": 28,
      "abbreviationCount": 28
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3, Randomized, Open-label Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) with Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Chemotherapy and Autologous Stem Cell Transplantation",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment 9",
      "versionDate": "20 July 2021",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9",
        "nc_10",
        "nc_11",
        "nc_12",
        "nc_13",
        "nc_14",
        "nc_15"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "CSR",
          "expansion": "Clinical Study Report"
        },
        {
          "abbreviation": "OS",
          "expansion": "Overall Survival"
        },
        {
          "abbreviation": "PD",
          "expansion": "Disease Progression"
        },
        {
          "abbreviation": "Dara-SC",
          "expansion": "Daratumumab Subcutaneous"
        },
        {
          "abbreviation": "Dara-IV",
          "expansion": "Daratumumab Intravenous"
        },
        {
          "abbreviation": "IRR",
          "expansion": "Infusion-Related Reaction"
        },
        {
          "abbreviation": "rHuPH20",
          "expansion": "Recombinant Human Hyaluronidase PH20"
        },
        {
          "abbreviation": "PFS",
          "expansion": "Progression Free Survival"
        },
        {
          "abbreviation": "DRd",
          "expansion": "Daratumumab plus Lenalidomide and Dexamethasone"
        },
        {
          "abbreviation": "IDMC",
          "expansion": "Independent Data Monitoring Committee"
        },
        {
          "abbreviation": "Rd",
          "expansion": "Lenalidomide and Dexamethasone"
        },
        {
          "abbreviation": "IMWG",
          "expansion": "International Myeloma Working Group"
        },
        {
          "abbreviation": "PK",
          "expansion": "Pharmacokinetics"
        },
        {
          "abbreviation": "ECOG",
          "expansion": "Eastern Cooperative Oncology Group"
        },
        {
          "abbreviation": "ePRO",
          "expansion": "Electronic Patient-Reported Outcome"
        },
        {
          "abbreviation": "MRD",
          "expansion": "Minimal Residual Disease"
        },
        {
          "abbreviation": "CR",
          "expansion": "Complete Response"
        },
        {
          "abbreviation": "sCR",
          "expansion": "Stringent Complete Response"
        },
        {
          "abbreviation": "C1D1",
          "expansion": "Cycle 1 Day 1"
        },
        {
          "abbreviation": "PR",
          "expansion": "Partial Response"
        },
        {
          "abbreviation": "PC",
          "expansion": "Plasma Cell"
        },
        {
          "abbreviation": "FLC",
          "expansion": "Free Light Chain"
        },
        {
          "abbreviation": "ICMJE",
          "expansion": "International Committee of Medical Journal Editors"
        },
        {
          "abbreviation": "G-CSF",
          "expansion": "Granulocyte Colony-Stimulating Factor"
        },
        {
          "abbreviation": "MRU",
          "expansion": "Medical Resource Utilization"
        },
        {
          "abbreviation": "eCRF",
          "expansion": "Electronic Case Report Form"
        },
        {
          "abbreviation": "PBMC",
          "expansion": "Peripheral Blood Mononuclear Cell"
        },
        {
          "abbreviation": "IHC",
          "expansion": "Immunohistochemistry"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3, Randomized, Open-label Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) with Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Chemotherapy and Autologous Stem Cell Transplantation",
        "version": "Amendment 9",
        "versionDate": "20 July 2021"
      },
      "sections": [
        {
          "number": "",
          "title": "SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "",
          "title": "TIME AND EVENTS SCHEDULE OVERVIEW",
          "type": "Study Procedures"
        },
        {
          "number": "",
          "title": "TIME AND EVENTS SCHEDULE, DOSE ADMINISTRATION",
          "type": "Treatment"
        },
        {
          "number": "",
          "title": "ABBREVIATIONS",
          "type": "Other"
        },
        {
          "number": "1",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Background"
            },
            {
              "number": "1.2",
              "title": "Daratumumab"
            },
            {
              "number": "1.3",
              "title": "Lenalidomide"
            },
            {
              "number": "1.4",
              "title": "Lenalidomide and Daratumumab"
            },
            {
              "number": "1.5",
              "title": "Overall Rationale for the Study"
            }
          ]
        },
        {
          "number": "2",
          "title": "OBJECTIVES AND HYPOTHESIS",
          "type": "Objectives",
          "subsections": [
            {
              "number": "2.1",
              "title": "Objectives"
            },
            {
              "number": "2.2",
              "title": "Hypothesis"
            }
          ]
        },
        {
          "number": "3",
          "title": "STUDY DESIGN AND RATIONALE",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Overview of Study Design"
            },
            {
              "number": "3.2",
              "title": "Study Design Rationale"
            }
          ]
        },
        {
          "number": "4",
          "title": "SUBJECT POPULATION",
          "type": "Study Population",
          "subsections": [
            {
              "number": "4.1",
              "title": "Inclusion Criteria"
            },
            {
              "number": "4.2",
              "title": "Exclusion Criteria"
            },
            {
              "number": "4.3",
              "title": "Prohibitions and Restrictions"
            }
          ]
        },
        {
          "number": "5",
          "title": "TREATMENT ALLOCATION AND BLINDING",
          "type": "Treatment"
        },
        {
          "number": "6",
          "title": "DOSAGE AND ADMINISTRATION",
          "type": "Treatment",
          "subsections": [
            {
              "number": "6.1",
              "title": "Daratumumab (Arm B Only)"
            },
            {
              "number": "6.2",
              "title": "Lenalidomide (Arm A and Arm B)"
            },
            {
              "number": "6.3",
              "title": "Dexamethasone (Arm A and Arm B)"
            }
          ]
        },
        {
          "number": "8",
          "title": "CONCOMITANT THERAPY",
          "type": "Treatment",
          "subsections": [
            {
              "number": "8.2",
              "title": "Permitted Therapies"
            },
            {
              "number": "8.3",
              "title": "Prohibited Therapies"
            },
            {
              "number": "8.4",
              "title": "Subsequent Therapies"
            }
          ]
        },
        {
          "number": "9",
          "title": "STUDY EVALUATIONS",
          "type": "Assessments",
          "subsections": [
            {
              "number": "9.1",
              "title": "Study Phases and Visit Conduct"
            },
            {
              "number": "9.2",
              "title": "Efficacy"
            },
            {
              "number": "9.3",
              "title": "Pharmacokinetics and Immunogenicity"
            },
            {
              "number": "9.8",
              "title": "Safety Evaluations"
            }
          ]
        },
        {
          "number": "11",
          "title": "STATISTICAL METHODS",
          "type": "Statistics",
          "subsections": [
            {
              "number": "11.2",
              "title": "Sample Size Determination"
            },
            {
              "number": "11.3",
              "title": "Efficacy Analysis"
            },
            {
              "number": "11.10",
              "title": "Interim Analysis"
            }
          ]
        },
        {
          "number": "12",
          "title": "ADVERSE EVENT REPORTING",
          "type": "Safety",
          "subsections": [
            {
              "number": "12.3.1",
              "title": "All Adverse Events"
            },
            {
              "number": "12.3.2",
              "title": "Serious Adverse Events"
            }
          ]
        },
        {
          "number": "17",
          "title": "STUDY ADMINISTRATION",
          "type": "Other",
          "subsections": [
            {
              "number": "17.9.1",
              "title": "Final OS Analysis/End of Study"
            }
          ]
        }
      ]
    }
  }
}